Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler talked with Proactive's Stephen Gunnion about the company’s recent milestone—the first human dose of its proprietary CAR-T cell therapy, HG-CT-1, for treating relapsed refractory acute myeloid leukemia (AML) in adults. This is a significant development in tackling one of the deadliest blood cancers, which has a low remission rate with current frontline therapies.
Sandler explained, “We are trying to cure a very deadly disease which is called acute myeloid leukemia... This is one of the worst blood cancers in existence.” He highlighted that only 30% of newly diagnosed patients respond to frontline therapies, leaving a significant need for more effective treatments.
The therapy uses third-generation chimeric antigen receptor (CAR) technology, which, according to Sandler, offers the same efficacy as the current second-generation CARs but with enhanced safety. The company is poised to accelerate its clinical trials, pending resource availability, with the potential to infuse patients every 14 days after the fourth patient.
With the first patient showing no adverse effects so far, Hemogenyx is hopeful about the progress of HG-CT-1 and is ready to scale up manufacturing as new patients are identified.
For more insightful interviews and the latest updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content.
#Hemogenyx #CAR_Therapy #HGCT1 #AML #CancerTreatment #Biotechnology #HealthcareInnovation #ClinicalTrials #BloodCancer #Investing
